DK4074703T3 - Pyridinyl-(aza)indolsulfonamider - Google Patents

Pyridinyl-(aza)indolsulfonamider Download PDF

Info

Publication number
DK4074703T3
DK4074703T3 DK22171413.2T DK22171413T DK4074703T3 DK 4074703 T3 DK4074703 T3 DK 4074703T3 DK 22171413 T DK22171413 T DK 22171413T DK 4074703 T3 DK4074703 T3 DK 4074703T3
Authority
DK
Denmark
Prior art keywords
aza
pyridinyl
indole sulfonamides
sulfonamides
indole
Prior art date
Application number
DK22171413.2T
Other languages
English (en)
Inventor
Christa E Mueller
Joerg Hockemeyer
Ali El-Tayeb
Nader Boshta
Mahmoud Rashed
Cécile Pegurier
Laurent Provins
Alvaro Cardenas
Marie Ledecq
Original Assignee
Ucb Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Gmbh filed Critical Ucb Pharma Gmbh
Application granted granted Critical
Publication of DK4074703T3 publication Critical patent/DK4074703T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK22171413.2T 2018-06-19 2019-06-18 Pyridinyl-(aza)indolsulfonamider DK4074703T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18178429 2018-06-19
EP19157936 2019-02-19
EP19733686.0A EP3810591B1 (en) 2018-06-19 2019-06-18 Pyridinyl and pyrazinyl-(aza)indolsulfonamides

Publications (1)

Publication Number Publication Date
DK4074703T3 true DK4074703T3 (da) 2024-01-29

Family

ID=67070797

Family Applications (2)

Application Number Title Priority Date Filing Date
DK22171413.2T DK4074703T3 (da) 2018-06-19 2019-06-18 Pyridinyl-(aza)indolsulfonamider
DK19733686.0T DK3810591T3 (da) 2018-06-19 2019-06-18 Pyridinyl- og pyrazinyl-(aza)indolsulfonamider

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK19733686.0T DK3810591T3 (da) 2018-06-19 2019-06-18 Pyridinyl- og pyrazinyl-(aza)indolsulfonamider

Country Status (26)

Country Link
US (1) US11939319B2 (da)
EP (2) EP4074703B1 (da)
JP (1) JP7382973B2 (da)
KR (1) KR102799157B1 (da)
CN (1) CN112469710B (da)
AU (1) AU2019289788B2 (da)
BR (1) BR112020025618A2 (da)
CA (1) CA3100795A1 (da)
CL (1) CL2020003202A1 (da)
DK (2) DK4074703T3 (da)
ES (2) ES2929992T3 (da)
FI (1) FI4074703T3 (da)
HR (2) HRP20240071T1 (da)
HU (2) HUE065411T2 (da)
IL (1) IL279428B2 (da)
LT (2) LT4074703T (da)
MX (1) MX2020012173A (da)
NZ (1) NZ771366A (da)
PL (2) PL3810591T3 (da)
PY (1) PY1947754A (da)
RS (2) RS63760B1 (da)
SG (1) SG11202012421TA (da)
SI (1) SI4074703T1 (da)
TW (1) TWI857957B (da)
UY (1) UY38266A (da)
WO (1) WO2019243303A1 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3983384B1 (en) * 2019-06-17 2023-10-11 UCB Pharma GmbH N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis
JP2023531358A (ja) * 2020-05-01 2023-07-24 ザ チルドレンズ メディカル センター コーポレーション ミエリン形成を促進する組成物および方法
JP7688690B2 (ja) 2020-07-28 2025-06-04 スーチュアン・コールン-バイオテック・バイオファーマシューティカル・カンパニー・リミテッド ピリミジン系化合物の塩、結晶形およびその調製方法
CN112375027B (zh) * 2020-12-07 2023-03-31 中国药科大学 吲哚磺酰胺类衍生物及其医药用途
SI4298092T1 (sl) * 2021-02-26 2026-04-30 F. Hoffmann-La Roche Ag Novi derivati pirimidin-2-il sulfonamida
US20240299385A1 (en) * 2021-06-04 2024-09-12 Rewind Therapeutics Nv 3-pyrrolylsulfonamide compounds as gpr17 antagonists
WO2024017856A1 (en) 2022-07-20 2024-01-25 F. Hoffmann-La Roche Ag Novel isoquinolinone, pyrrolopyridinone and thienopyridinone sulfonamide derivatives
CN119546608A (zh) * 2022-07-20 2025-02-28 豪夫迈·罗氏有限公司 新颖咪唑并吡啶和吡唑并吡啶磺酰胺衍生物
WO2024017863A1 (en) 2022-07-20 2024-01-25 F. Hoffmann-La Roche Ag Novel pyrimidinyl and triazinyl sulfonamide derivatives
US20260028335A1 (en) * 2022-07-20 2026-01-29 Hoffmann-La Roche Inc. Novel isothiazol-3-yl and isoxazol-3-yl sulfonamide compounds
CN119546572A (zh) 2022-07-20 2025-02-28 豪夫迈·罗氏有限公司 新颖的萘基和异喹啉磺酰胺衍生物
IL318162A (en) * 2022-08-26 2025-03-01 Hoffmann La Roche PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES ARE DISTRIBUTED
KR20250121546A (ko) * 2022-11-20 2025-08-12 마이로발란 테라퓨틱스, 인크. Gpr17 조절제 및 이의 용도
JP2025539466A (ja) * 2022-12-02 2025-12-05 リワインド セラピューティクス エン ヴェー 縮合ピロリルスルホンアミド化合物
WO2024153233A1 (en) * 2023-01-19 2024-07-25 Nanjing Immunophage Biotech Co., Ltd Compounds and their uses as gpr17 antagonists
CN116283748A (zh) * 2023-02-21 2023-06-23 康化(上海)新药研发有限公司 2,5-二氯-3-甲氧基吡啶的合成方法
GB2700773A (en) 2024-05-23 2026-03-11 Pheno Therapeutics Ltd Compounds
WO2025243044A1 (en) 2024-05-23 2025-11-27 Pheno Therapeutics Limited Compounds
GB202418759D0 (en) * 2024-12-19 2025-02-05 Nxera Pharma Uk Ltd Therapeutic compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702680D0 (sv) 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
SE9904750D0 (sv) 1999-12-23 1999-12-23 Pharmacia & Upjohn Ab New formulation, use and method
US7833722B2 (en) 2004-04-27 2010-11-16 Takeda Pharmaceutical Company Limited Ligands for G protein-coupled receptor protein and use thereof
ITMI20042007A1 (it) * 2004-10-21 2005-01-21 Consiglio Nazionale Ricerche "modulatori del ricettore gpr17 e loro impieghi terapeutici"
EP1962837A4 (en) 2005-12-20 2011-12-14 Teikoku Pharma Usa Inc METHODS OF PERCUTANEOUS DELIVERY OF INDOLIC SEROTONIN RECEPTOR AGONIST AND PERCUTANEOUS COMPOSITIONS FOR USE THEREIN
EP2162183B1 (de) 2007-06-25 2019-06-26 AMW GmbH Elektrophoretisches transdermales applikationssystem
US20110220151A1 (en) 2010-03-11 2011-09-15 Swinford Jerry L Method and Apparatus for Washing Downhole Tubulars and Equipment
IT1402549B1 (it) * 2010-11-03 2013-09-13 Univ Pisa Composti e composizioni che modulano gpr17 e loro usi terapeutici e diagnostici
EP2567698B1 (en) 2011-09-07 2014-02-12 Rheinische Friedrich-Wilhelms-Universität Bonn GPR 17 agonists and screening assay
US9879030B2 (en) 2012-05-09 2018-01-30 Universita′ Degli Studi Di Milano GPR17 receptor modulators
TWI754702B (zh) 2016-12-28 2022-02-11 德商Ucb製藥有限公司 (氮雜)吲哚-和苯並呋喃-3-磺醯胺類

Also Published As

Publication number Publication date
HUE065411T2 (hu) 2024-05-28
LT3810591T (lt) 2022-11-25
CL2020003202A1 (es) 2021-05-07
KR20210022675A (ko) 2021-03-03
LT4074703T (lt) 2024-02-26
AU2019289788B2 (en) 2024-07-11
CA3100795A1 (en) 2019-12-26
BR112020025618A2 (pt) 2021-03-23
HUE060128T2 (hu) 2023-01-28
MX2020012173A (es) 2021-01-29
TW202016088A (zh) 2020-05-01
UY38266A (es) 2020-01-31
IL279428B2 (en) 2024-03-01
IL279428A (en) 2021-01-31
CN112469710B (zh) 2024-05-14
IL279428B1 (en) 2023-11-01
JP2021527690A (ja) 2021-10-14
ES2929992T3 (es) 2022-12-05
DK3810591T3 (da) 2022-10-31
RS65272B1 (sr) 2024-03-29
CN112469710A (zh) 2021-03-09
FI4074703T3 (fi) 2024-02-01
PY1947754A (es) 2020-08-26
EP4074703A1 (en) 2022-10-19
US20210206749A1 (en) 2021-07-08
AU2019289788A1 (en) 2021-01-21
SI4074703T1 (sl) 2024-03-29
KR102799157B1 (ko) 2025-04-21
ES2972491T3 (es) 2024-06-13
US11939319B2 (en) 2024-03-26
NZ771366A (en) 2025-03-28
HRP20240071T1 (hr) 2024-03-29
TWI857957B (zh) 2024-10-11
EP3810591A1 (en) 2021-04-28
EP4074703B1 (en) 2023-11-29
JP7382973B2 (ja) 2023-11-17
RS63760B1 (sr) 2022-12-30
EP3810591B1 (en) 2022-08-10
PL3810591T3 (pl) 2022-12-19
SG11202012421TA (en) 2021-01-28
HRP20221290T1 (hr) 2022-12-23
PL4074703T3 (pl) 2024-05-13
WO2019243303A1 (en) 2019-12-26

Similar Documents

Publication Publication Date Title
EP3801265B1 (en) URINARY FLOWMETER
HUE065411T2 (hu) Piridinil-(aza)indolszulfonamidok
EP3890716A4 (en) COMBINATION THERAPIES
EP3849534A4 (en) COMBINATION THERAPIES
DK3810602T3 (da) Forbindelser
EP3846674C0 (en) VAGINAL SPECULUM
EP3555124C0 (en) TCR NYESO
EP3549340A4 (en) MULTI-HYPOTHESIS FUSION MODE
PL3897842T3 (pl) Pochodne bicykliczne
DK4177504T3 (da) Forbindelse
HUE051348T2 (hu) Aromás szulfonamid származékok
LT3830085T (lt) Deuterinti lanifibranoro dariniai
EP3781060A4 (en) CRYOPROBE
EP3763127A4 (en) FAST DST-7
DK3768669T3 (da) Piperazinazaspiroderivater
EP3872558A4 (en) OPTICAL ISOLATOR
DK3838734T3 (da) Redningsbåd
PT3625224T (pt) Derivados de indol n-substituídos
EP3784463A4 (en) Fluorosulfones
EP3810860C0 (en) COUPLER
DK3810633T3 (da) Forbindelser
EP3792200A4 (en) TANK TANK
EP3745904C0 (de) Stockgriff
EP3899155A4 (en) IMPROVED CONNECTOR
IL283745A (en) Connectivity intermediary